Yüklüyor......
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of...
Kaydedildi:
| Yayımlandı: | J Clin Invest |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Clinical Investigation
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810481/ https://ncbi.nlm.nih.gov/pubmed/33463535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI143226 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|